中文名：Ipragliflozin,抑制劑
英文名：Ipragliflozin
中文別名：(1S)-1,5-脫水-1-C-[3-[(1-苯并噻吩-2-基)甲基]-4-氟苯基]-D-葡糖醇
英文別名：Ipragliflozin|761423-87-4|suglat|ASP1941|ASP-1941|Ipragliflozin [INN]|Ipragliflozin (ASP1941)|(2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol|3N2N8OOR7X|CHEMBL2018096|(1S)-1,5-Anhydro-1-c-[3-[(1-benzot
純度：97%
貨號：I177384
包裝：100mg、25mg、10mg
Cas號：761423-87-4
存儲溫度：-20°C儲存
產(chǎn)品介紹：
Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. IC50 value: 2.8 nM Target: SGLT2 in vitro: Ipragliflozin potently and selectively inhibited human, rat, and mouse SGLT2 at nanomolar ranges and exhibited stability against intestinal glucosidases. in vivo: Ipragliflozin showed good pharmacokinetic properties following oral dosing, and dose-dependently increased urinary glucose excretion, which lasted for over 12 h in normal mice. Oral administration of ipragliflozin increased urinary glucose excretion in a dose-dependent manner, an effect which was significant at doses of 0.3 mg/kg or higher and lasted over 12 h. Single administration of ipragliflozin dose-dependently increased urinary glucose excretion, reduced blood glucose and plasma insulin levels, and improved glucose intolerance .
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應(yīng)頁面：https://www.aladdin-e.com/zh_cn/I177384.html
關(guān)鍵字： (1S)-1,5-脫水-1-C-[3-[(1-苯并噻吩-2-基)甲基]-4-氟苯基]-D-葡糖醇;Ipragliflozin;761423-87-4;suglat
上海阿拉丁生化科技股份有限公司是A股上市公司（（股票代碼：688179），專注于科研試劑的研發(fā)、生產(chǎn)和銷售，已陸續(xù)建立多個工廠和研發(fā)中心。作為領(lǐng)軍企業(yè)，阿拉丁始終堅持質(zhì)量第一，連續(xù)13年被評為“最受歡迎試劑品牌”。
阿拉丁目前常備庫存試劑產(chǎn)品品種超過7萬種，SKU總數(shù)超過46萬，產(chǎn)品線涵蓋了化學試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個領(lǐng)域，是國內(nèi)少數(shù)化學試劑到生物試劑全面發(fā)展的國產(chǎn)試劑品牌，產(chǎn)品同步發(fā)布在我們國內(nèi)外電商平臺。